GSK is embarking on a journey with CAMP4 Therapeutics, paying $17.5 million upfront to collaborate on regulatory ...
The function of non-coding RNA in the cell has long been a mystery to researchers. Unlike coding RNA, non-coding RNA does not produce proteins – yet it exists in large quantities. A research team from ...
When the drug fomivirsen was approved by the FDA in 1998 for the treatment of cytomegalovirus retinitis in patients with HIV/AIDs, it was hailed as a milestone in drug discovery because it was the ...
TipRanks on MSN
CAMP4, GSK form RNA therapeutics collaboration agreement
CAMP4 Therapeutics Corporation ( ($CAMP) ) has provided an announcement. On December 17, 2025, CAMP4 Therapeutics entered into a strategic ...
Thank you for your article on antisense 1 and for letting us know that the subject is very much alive. Although antisense is an "RNA therapeutic" in that the target is mRNA, actually in almost all ...
Courtesy of Antisense Therapeutics Ltd. Antisense strategies use polymeric nucleic acids or nucleic acid analogs to bind to and silence specific messenger RNAs. The silencing can be caused either by ...
An antisense therapy restores production of the protein FMRP in cell samples taken from patients with fragile X syndrome. This breakthrough was possible because of the novel findings, also presented ...
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q3z4pf/pharmasphere) has announced the addition of the "PharmaSphere ...
So far, 2013 has been a good year for antisense technology. In fact, it’s been great. In January the FDA OK’d Isis Pharmaceuticals’ Kynamro™ (mipomersen sodium), the only currently marketed antisense ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results